Introduction
Fragile sites are specific chromosomal regions prone to genetic instability, chromosomal breakage and rearrangements, and thus their disruption may play a mechanistic role in carcinogenesis. In gastric cancer, chromosomal regions 3p (Gemma et al., 1997) , 5q (Tamura et al., 1996) , 7q (Kuniyasu et al., 1994) , 11q , 17p (Sano et al., 1991) , and 18q (Uchino et al., 1992) have been identified as fragile sites. The FHIT (fragile histidine triad) gene, a putative tumor suppressor gene, is located at human chromosome 3p14.2, a region of high fragility (FRA3B) and recombination, as well as of specific deletions and translocation in several cancers Croce et al., 1999) . Homozygous deletions within the FHIT locus, genomic DNA rearrangements, and aberrant FHIT transcripts have been described in a variety of human cancer cell lines and tumor tissues, including lung cancer (Sozzi et al., 1996b) , gastrointestinal tumors , breast cancers , head and neck squamous cell carcinomas (Virgilio et al., 1996) , and Merkel cell carcinomas (Sozzi et al., 1996a) . A good correlation between alterations of the FHIT gene and its reduced protein expression has been observed . In addition, suppression of tumorigenicity and tumor cell growth in nude mice by replacement of exogenous wild-type FHIT gene point to the role of FHIT as a tumor suppressor gene Ji et al., 1999) . Despite numerous reports on the status of the FHIT gene, the question of whether the FHIT gene acts as a classical tumor suppressor is still controversial.
High frequency of aberrant FHIT transcripts in various cancers, especially in epithelial type, is the most prominent finding. Large deletions and insertions within coding region have been identified in several types of cell lines and primary tumors, even matched normal tissues, by sequence analysis of RT-PCR-rescued transcripts of the FHIT gene. Such abnormalities usually occurred at exon-intron junction, mostly accompanied by a normal-sized transcript. Exon 5 and exon 8 were targets for more frequent deletions . Thus, most of truncated transcripts are missing the start codon of the FHIT gene and cannot encode functional protein. Actually, few studies analyzed truncated FHIT protein expression. Furthermore, there has been conflicting data concerning occurrence of aberrant FHIT transcripts in various cancers, including gastric cancer.
Chromosomal instability including genomic rearrangement and breakage Croce et al., 1999) , disruption of RNA splicing mechanism (=mis-splicing) (Gayther et al., 1997) , or hypermethylation of the FHIT promoter region (Tanaka et al., 1998; Laux et al., 1999) , as yet unidentified, can be considered possible mechanisms involved for aberrant transcription of the FHIT pre-mRNA.
We previously investigated altered expression of FHIT gene in primary gastric adenocarcinomas. Using 35 tumors and their matched normal tissues, we identified significant rate of LOH at D3S1300, high frequency of aberrant FHIT transcripts, and reduced FHIT protein expression (Lee et al., 2001) . Focusing on the FHIT transcripts, 48 aberrant-sized FHIT transcripts with various lengths and number have been further characterized in this study. The results provide the evidence that FHIT is frequently altered in gastric adenocarcinomas by aberrant splicing and activation of cryptic splice acceptor sites within intron 5 and/or exon 6, and suggest that different types of aberrant transcripts may result during the multi-step splice processing.
Materials and Methods

RNA isolation and reverse transcription
Total RNA was extracted from frozen tissues by the total RNA isolation kit (Totally RNA, Ambion Inc., Austin, Texas, USA) according to manufacturer's instruction. Reverse transcription was performed in 20 µl final volume containing 1 µg RNA, 5 mM MgCl 2 , 1 mM of each dNTP, and 2.5 U MuLV reverse transcriptase (Perkin Elmer, Norwalk, CT, USA). The samples were first denatured for 5 min at 70 o C and annealed with oligo d(T) 16 primers at room temperature for 3 min, and then 2.5 U MuLV reverse transcriptase were added. Samples were incubated at 37 o C for 60 min. Inactivating the enzyme at 95 o C for 5 min then stopped the reaction.
RT-PCR and cDNA sequencing
Twenty microliter of cDNA reaction was used for the first PCR amplification in a volume of 100 µl containing 0.5 µM of primers 5U2 (5'-CATCCTGGAAGCTTTGAAGC-TCA-3') and 3D2 (5'-TCACTGGTTGAAGAATACAGG-3'), as published by Ohta et al. (1996) Amplified products were diluted 20-fold with TE buffer (10 mM Tris-HCl, 1 mM EDTA), and 1 µl was used for the second-round PCR by the nested primers 5U1 (5'-TCCGTAGTGCTATCTACA-TC-3') and 3U1 (5'-CATGCTGATTCAGTTCCTCTTGG-3') in the same conditions as the first-round PCR, except for 30 cycles of reaction instead of 25 cycles. The nested PCR products were resolved in 10% polyacrylamide gels. Selected aberrant transcripts were recovered from ethidium bromide-stained gels and were cloned into a pGEM-T vector system according to manufacturer's instruction (Promega, Madison, WI, USA). DNA inserts from positive colonies were amplified with T7 and SP6 universal primers and sequenced using an ABI Prism BigDye Terminator Cycle Sequencing kit and an ABI 310 sequencer (Perkin Elmer). DNA sequences were compared to the GenBank databases utilizing the Blast program available at the web site, "http://www. ncbi.nlm.nih.gov".
Results
To study abnormal FHIT transcription in gastric carcinogenesis, 35 gastric adenocarcinomas were analyzed for a 707-bp cDNA fragment, which encompass exon 3 to 10 of the FHIT gene, using nested RT-PCR and sequencing. In addition to the wild-type FHIT transcript, small-sized transcripts with various number and lengths were observed in 20 of 35 (57.1%) tumors, with two Band patterns for lanes 1-7 were reported earlier (Lee et al., 2001) . tumors expressing only abnormal FHIT transcripts. A total of 48 aberrant transcripts were characterized from the 20 tumors. Sixty-two point five percent (30/48) of these transcripts contained only deletions, the others (37.5%) had deletion with insertion of intron sequence. Aberrant band sizes were diverse (~360 −~830 bp), with a range of 1 to 7 bands. No FHIT transcript was expressed in one case (Figure 1 ).
All the PCR products were excised from the polyacrylamide gel and subsequently cloned into a pGEM-T vector system. Sequence analysis of normal-sized transcripts showed no deletion or insertion in any case. Figure 2 shows a typical sequence of 9 types of aberrant transcripts with losses of various exons from 3 to 8, resulting in fusion of exons 2 and 4, 2 and 5, 3 and 5, 4 and 8, or 4 and 9. Transcripts with fusion of exons 2, 3, or 4 and the last 69 nucleotides (nt) of exon 6 (nt 181 to 249 of the FHIT cDNA sequence; Ohta et al., 1996) were frequently observed. The first 11-bp deletion (nt 450 to 460) at the 5' end of exon 10, ATGTTTTTCAG, was detected in 3 cases (cases 3B, 5B, and 13A) with losses of other exons.
Sequence analysis of 48 aberrant-sized transcripts revealed that aberrant FHIT transcripts lacked one or more exons of the FHIT or lacked exons with the insertion of intron sequence as previously reported (Lee et al., 2001) . Loss of the sequence from exon 5 to the first 77 nt of exon 6 (nt 17 to 180) was the most common abnormality (Table 1) . The use of a cryptic splice acceptor sequence (-AG-) at position 179-180 resulted in fusion of exon 4 and the last 69 nt of exon 6. The deletion of this type was detected in 17 aberrant transcripts including 9 cases with deletion only and 8 cases with both deletion and insertion. Of the inserts with various lengths (59-, 81-, 112-, or 138-bp) detected in the above 8 cases, a 138-bp insertion is most frequently observed in 10 of total 20 tumor tissues displaying aberrant transcripts. This insert of identical size was previously reported in a variety of human cancer cell lines and tumor tissues, including lung cancer cell lines and primary lung tumors , nasopharyngeal cancers (Sung et al., 2000) as well as squamous cell cancers of cervix . Other aberrant transcripts involving loss of exon 4 or loss of exon 4 through the first 77 nt of exon 6 (nt -110 to 180) were detected in 7 or 6 cases, respectively. Three of the latter 6 cases also contained a 59-bp or 138-bp insertion. The exon 4 was frequently spliced to several coding regions, including exon 6, 8, 9, and the last 69 nt of exon 6, which frequently act as an acceptor for exon 2, 3, and 4. A Blast search in GenBank database identified that the origin of the inserts with various sizes is the part of intron 5 sequences in the FHIT gene. Figure 3 shows the nucleotide sequence of the inserts identified in 18 aberrant transcripts from 12 tumors. All of the insertions occurred in combination with in-frame deletions. The sizes of the inserts were diverse (59-, 81-, 103-, 112-, 138-, 158-, and 250-bp), but some of them were overlapped. Some aberrant FHIT transcripts with 138-bp, 81-bp, or 59-bp insertions were found between various exons (E3, E4, or E5) and the last 69 nt of exon 6. Some insertions were the parts of intron sequence flanking on the coding exon, indicative of aberrant splicing through the selection of cryptic splice site in intron sequence. An 112-bp or 103-bp insertion was identical to the intron 5 sequence flanking on the 5'-side of the coding exon 6 or on the 3'-side of the coding exon 5, respectively. Some insertions were overlapping; a 250-bp insertion replacing exon 5 comprised this 138-bp as well as 112-bp sequence identical to the insert in aberrant transcripts 6A and 26A. Another 158-bp insertion comprised this 112-bp and the other 46-bp insertion. The deletions or insertions within cDNA sequence occurred at exon-intron junction of genuine splice site, or at cryptic splice site located within exon or intron. Analysis of the sequence flanking the deletion or insertion revealed that two distinctive types of conserved sequences -the GU-AG and AC-AG motifs-were placed in the beginning and the end of the deleted portions of aberrant FHIT transcripts. Proportion of two motifs in splice sites is 58.5% for GU-AG and 33.8% for AC-AG.
Multi-step splice patterns were observed in several tumor specimens, in which intron sequences remained were finally spliced out (Figure 4) . In cases 18, 24, and 26, transcript "A" lacking exon 4 and/or 5 with 138-bp, 250-bp (138-bp and 112-bp), or 112-bp (59-bp and 53-bp) inserts, respectively, appeared to be a precursor of transcripts B, C, or D that underwent additional downstream processing.
Discussion
Characterization of aberrant transcripts in tumor tissues may be a basic step toward understanding the possible role of the FHIT gene in carcinogenesis. Early studies of a number of human tumor types showed that FHIT transcription was frequently altered, and a significant proportion of such alterations were shown to correlate with deletions within the FHIT gene Druck et al., 1997) . In this study, investigation of primary gastric cancers demonstrated 48 aberrant transcripts in 57.1% (20/35) of the tumors. The frequency is significantly higher than 10 in 46.7% (7/15) of Chen et al. (1997) , and 11 aberrant transcripts in 35% (11/32) of Baffa et al. (1998) . To extract the abnormal bands, we used 10% polyacrylamide gel instead of agarose gel because low resolution of agarose gel results in co-migration of cDNA fragments and makes the interpretation of results harder. Here, many more aberrant transcripts were observed, although there is a background of nonspecific bands. Most of tumor specimens had multiple bands. Sequence analysis confirmed that faint bands of smaller size, which were not seen in agarose gels, were low-abundance transcripts that were alternatively spliced.
Aberrant transcripts of different size were the results of exon skipping and/or insertion of FHIT intron sequence, or selection of cryptic splice sites. Excepting the regions of deletions or insertions, the exons retained in all cases of aberrant transcripts were correctly spliced, indicating the correct use of their splicing signals. An 11-bp deletion from nt 450 to 460 was also identified as described previously (Muller et al., 1998; Nakagawa et al., 1999) . The exons 5-6 deleted splice variants, with or without loss of exon 4 and/or 7, were the prominent transcripts. These results were consistent with those found in other various carcinomas (Gemma et al., 1997; Hendricks et al., 1997) . Considering the facts that the translation initiation codon is located in exon 5, most of aberrant transcripts may not generate any protein products.
A recent Blast search in GenBank database identifies the origin of the inserts whose sequences remained unknown in most of previous studies. From the findings that all of the inserts seen in our study were the part of intron 5 sequence and usually were found between various exons (E2, E3, or E4) and the last 69 nt within exon 6, it is possible that the inserts, replacing of the missing exons, occurred by aberrant splicing and/or activation of the cryptic splice site within intron 5 and exon 6 of the FHIT gene. It is noteworthy that all of the insertions, except for case 30B, occurred in aberrant transcripts with loss of exon 5, although these transcripts lacked variable number of exons. In previous study, loss or reduced expression of FHIT protein and its strong association with occurrence of aberrant FHIT transcript in cervical carcinomas suggested that FHIT gene inactivation might contribute to clonal outgrowth during gastric carcinogenesis and that aberrant expression might be a common mechanism impairing the FHIT gene . Although some type of silencing mechanism might be involved, the reason why the aberrant transcripts have anything to do with the absence of FHIT expression requires further study. In this study, high rate of insertion and frequent activation of cryptic splice sites within intron 5 and/or exon 6 are striking, suggesting that splicing patterns of aberrant transcripts might correlate with the type of tumor or tissue. In addition, there appeared to be an order by which the additional splice processing occurs (Figure 4) . In cases 18, 24, and 26, their transcripts (A, B, C, or D) appeared to represent sequential processing for splicing out the intron sequence already inserted as a consequence of aberrant splicing, suggesting that sequential reactions of alternative splicing within a given tumor might be derived from a transcriptional unit in a single allele. Similar report has been described in Burkitt's lymphoma (Ferrer et al., 1999) .
These aberrations may be possibly due to the characteristics of the FHIT gene locus as fragile site. The structural alterations of FRA3B might interfere with the normal splicing and thus result in the generation of numerous aberrant transcripts. Indeed, homozygous deletions in the FHIT gene mostly involve intronic sequences within the FHIT gene locus (Boldog et al., 1997) , suggesting that partial deletions of the FHIT gene might affect transcription fidelity. Previous reports indicated that breakage and rearrangements of DNA within the FHIT gene resulted in occurrence of aberrant transcripts and subsequently reduced FHIT protein expression Baffa et al., 1998) . However, genomic deletions did not always affect exons of the gene. Indeed, aberrant FHIT transcripts were also found in tumors and in cell lines in which homozygous deletions of FHIT exons were not detected (Mao et al., 1996; Ozaki et al., 2000) , indicating genetic and/or epigenetic alterations in other regions, such as promoter regions. Although there is still controversy as to whether the aberrant FHIT transcripts reflect a chromosomal instability, these results provide evidence that splicing of the FHIT pre-mRNA is frequently altered and processed in gastric carcinomas, and suggest that the disruption of regulated pre-mRNA splicing may be occurred as a consequence of disturbed cellular function during malignant progression. The possible role of these mechanisms, however, remains to be determined in further studies of the genome structure.
